Sorafenib

The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis

“…LSMM patients treated with sorafenib as a monotherapy, which has an apparent volume of distribution of 213 L [51]. These two studies [20,37] demonstrated an association between LSMM and toxicity (OR 5.60; 95% CI 2.01-15.59; p = 0.001) with low heterogeneity (χ 2 = 0.33; I 2 = 0%).…”

Targeting stress granules: A novel therapeutic strategy for human diseases

“…Several small molecules have been reported to induce eIF2α phosphorylation and SG assembly, although different eIF2α kinases are employed. The Raf1/Mek/Erk kinase inhibitor sorafenib is approved for advanced hepatocarcinoma [ 76 ], and has previously been reported to induce ER stress by the activation of PERK phosphorylation of eIF2α [ 77 , 78 ]. Recently, it has been found that sorafenib induces SG formation in various cancer cells via PERK-mediated eIF2α phosphorylation [ 78 ].…”

Design, synthesis and biological evaluation of a new thieno[2,3-d]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines

“…1 H-NMR spectra were recorded on a Bruker 400 MHz spectrometer in d scale (ppm) using DMSO as a solvent and TMS as an internal standard. 13 C NMR spectra was run at Joel 100 MHz spectrometer in d scale J(Hz) using DMSO as a solvent and TMS as the internal standard. The LC-MS-MS system consisted of a Agilent 1200 HPLC system (Agilent technologies, CA) with a quaternary gradient pump (Agilent 1260 infinity), an online vacuum degasser, a column oven and an autosampler (Agilent 1260 infinity), coupled to a ABSCIEX Q TRAP 3200 mass spectrometer (ABSCIEX, Germany) equipped with an electrospray ionisation (ESI) interface.…”

“…1 H-NMR of KM6 revealed the appearance of two exchangeable protons corresponding to NHs at 9.8 and 10.0 ppm, aromatic protons at 7.08-8.34 ppm in addition to cyclohexyl protons at 1.78, 2.9 and 3.0 ppm. 13 [4,5]thieno[2,3-d]pyrimidin-4-yl)oxy)phenyl)urea] was prepared as stock solution at concentration 10 mM and was kept at À20 C. Immediately before use, it was serially diluted in RPMI 1640 to yield a concentration range of 2-32 mM.…”

“…Sorafenib is a diaryl urea derivative that acts as a multityrosine kinase inhibitor. It inhibits VEGFR-2, PDGFR, RAF, FLIT-3 and C-KIT and is used in treatment of hepatocellular and renal cell carcinomas 13 . It has been investigated in the treatment of TAM-resistant BC and showed remarkable sensitisation to TAM 14 .…”